|||
PCSK9抑制剂使用指南
PCSK9抑制剂使用指南
ASCVD
1. PCSK9 inhibitor therapy should be considered for ASCVD risk reduction in patients with stable atherosclerotic cardiovascular disease,particularly in those with additional ASCVD risk factors, on maximally-tolerated statin therapy 6 ezetimibe, with on-treatment LDL-C>70 mg/dL or non–HDL-C>100 mg/dL. Strength A, Quality: High
2. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with progressive atherosclerotic cardiovascular
disease on maximally-tolerated statin therapy 6 ezetimibe, and on-treatment LDL-C>70 mg/dL or non–HDL-C>100 mg/dL. Strength B, Quality: Moderate
Phenotypic FH/LDL-C>190 mg/dL3a PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients ages 40 to 79 years with phenotypic FH, pretreatment LDL-C>190 mg/dL, no uncontrolled ASCVD risk factors, or other key additional high-risk markers*, and on-treatment LDL-C>100 mg/dL or non–HDL-C>130 mg/dL on maximally-tolerated statin therapy 6 ezetimibe. Strength B, Quality: Moderate
3b PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients aged 40 to 79 years with phenotypic FH, pretreatment LDL-C $190 mg/dL, and the presence of either uncontrolled ASCVD risk factors, key additional high-risk markers*, or genetic confirmation of FH, and on-treatment LDL-C $70 mg/dL or non–HDL-C>100 mg/dL on maximally-tolerated statin 6 ezetimibe. Strength: B, Quality: Moderate
3c PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients aged 18 to 39 years with phenotypic FH, pretreatment LDL-C>190 mg/dL, and the presence of either uncontrolled ASCVD risk factors, key additional high-risk markers*, or genetic confirmation of FH, and on-treatment LDL-C>100 mg/dL or non–HDL-C>130 mg/dL on maximally-tolerated statin 6 ezetimibe. Strength: E, Quality: Low
3d PCSK9 inhibitor therapy may be considered to further reduce LDL-C in patients with homozygous familial hypercholesterolemia,
either of unknown genotype, or those known to be LDL receptor defective, on maximally-tolerated statin therapy 6 ezetimibe with LDL-C>70 mg/dL or non–HDL-C>100 mg/dL. Strength B, Quality: Moderate
Very-high-risk/statin intolerance
4. PCSK9 inhibitor therapy may be considered to further reduce LDL-C in selected very-high-risk patients who meet the definition of statin intolerance (as previously defined by the NLA Statin Expert Panel) and who require substantial additional atherogenic
cholesterol lowering, despite the use of other lipid-lowering therapies. Strength C, Quality: Low
指南目录
2016 ESC 和 AHA/AHA/HFSA慢性心力衰竭新指南解读
Archiver|手机版|科学网 ( 京ICP备07017567号-12 )
GMT+8, 2024-9-27 10:03
Powered by ScienceNet.cn
Copyright © 2007- 中国科学报社